.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Marco Mikus

Further involvements

22/09/2022
17:25 – 17:30 3 Min. 2 Min.
Poster
PS-5-14
Correlation between infection severity and antibody levels in COVID-19 convalescent plasma donors
13. Neue Blutprodukte – Neue Anwendungen, 19. COVID-19
22/09/2022
17:30 – 17:35 3 Min. 2 Min.
Poster
PS-5-15
Vaccine side effects after first, second and booster vaccination against SARS-CoV-2: Data from TüSeRe:exact study
19. COVID-19, 5. Infektionssicherheit von Blutprodukten